Product name
Recombinant Human Epiregulin
Code
CD01854
Biological activity
Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using Mouse Balb/c 3T3 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0 × 105 IU/mg.
Endotoxin
Less than 1 EU/μg of rHuEpiregulin as determined by LAL method.
Synonyms
Epiregulin,EPR, ER, Ep,EREG, Human
Sequence
VAQVSITKCS SDMNGYCLHG QCIYLVDMSQ NYCRCEVGYT GVRCEHFFL
Uniprot Accession
Molecular Weight
Approximately 5.6 kDa, a single non-glycosylated polypeptide chain containing 49 amino acids.
Formulation
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Background
Epiregulin encoded by the EREG gene in humans, is a member of the EGF family of growth factors. This family also includes epidermal growth factor (EGF), transforming growth factor (TGF)-alpha, amphiregulin (ARG), HB (heparin-binding)-EGF, betacellulin, and the various heregulins. Epiregulin is expressed mainly in the placenta and peripheral blood leukocytes and in certain carcinomas of the bladder, lung, kidney and colon. It stimulates the proliferation of keratinocytes, hepatocytes, fibroblasts and vascular smooth muscle cells. Additionally, it inhibits the growth of several tumor-derived epithelial cell lines. Human Epiregulin is initially synthesized as a glycosylated 19.0 kDa transmembrane precursor protein, which is processed by proteolytic cleavage to produce a 6.0 kDa mature secreted sequence.
Storage
-20ºC
Research area
Immunology
